Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example ArtifactAssessment: Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16

Generated Narrative: ArtifactAssessment 179698

version: 4; Last updated: 2023-12-06 08:41:24+0000

Profile: Adaptation

Artifact Author: Joanne Dehnbostel:

Artifact URL: https://fevir.net/resources/ArtifactAssessment/179698

Artifact Description:

This example of an Adaptation Profile shows the specific content that was changed when adapting one Recommendation Profile instance to create a new Recommendation Profile instance, serving a role of 'track changes' for structured data.

Artifact Status: active

identifier: FEvIR Object Identifier/179698

title: Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16

artifact: Recommendation: ADA Obesity Management Recommendation 8.16

content

informationType: Container

type: adapted element

classifier: string Datatype

path: overallSummary

Components

-InformationTypeSummaryTypeClassifier
*Comment

8.16 Metabolic surgery should be a recommended option to treat type 2 diabetes in screened surgical candidates with BMI ≥40 kg/m2 (BMI ≥37.5 kg/m2 in Asian Americans) and in adults with BMI 35.0–39.9 kg/m2 (32.5–37.4 kg/m2 in Asian Americans) who do not achieve durable weight loss and improvement in comorbidities (including hyperglycemia) with nonsurgical methods. A

Original Resource Content
*Response Rationale for Change to Resource ContentSuggested change
*Change Request

8.16 Metabolic surgery should be a recommended option to treat type 2 diabetes in screened surgical candidates with BMI ≥40 kg/m2 (BMI ≥37.5 kg/m2 in Asian Americans) and in adults with BMI 35.0–39.9 kg/m2 (32.5–37.4 kg/m2 in Asian Americans) who do not achieve durable weight loss and improvement in comorbidities (including hyperglycemia) with nonsurgical methods.

Suggested Change to Resource Content